Skip to main content

Edwards Lifesciences

Edwards Lifesciences Corporation is a world leader in medical innovation headquartered in Irvine, California, specializing in structural heart disease therapies and critical care monitoring systems. The company is globally recognized for developing groundbreaking artificial heart valves and pioneering transcatheter aortic valve replacement, known as TAVR technology. Its clinical portfolio includes advanced transcatheter and surgical tissue heart valves, mitral and tricuspid valve repair devices, and sophisticated hemodynamic monitoring equipment. Edwards Lifesciences collaborates with cardiovascular specialists to advance minimally invasive procedures that significantly shorten patient recovery times and improve overall clinical success rates. Driven by demographic trends toward aging global populations, the firm’s therapeutic interventions focus heavily on treatable structural heart conditions that disproportionately affect older adults. The corporation routinely dedicates substantial resources toward clinical trials, biomedical engineering, and digital health devices to expand treatment access for severe cardiac disorders. Guided by a strong patient-first culture, Edwards Lifesciences remains dedicated to enhancing life quality and longevity for cardiac patients across the globe.

70 of the funds FundTelligence covers report a position in Edwards Lifesciences.

Legal name
Edwards Lifesciences Corp.
Sector
Health Care
Country
United States
Funds holding it
70
Exposure themes
Ageing & Longevity, Age-Related Disease, Structural Heart Disease

Funds holding Edwards Lifesciences

Showing the 8 largest of 70 funds holding it.

Loading...